Company intelligence / Profile preview
Genuine Biotech
Pingdingshan, Chinaen.genuine-bio.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Genuine Biotech has received approval in China for Azvudine (July 2021) for COVID-19. The company has multiple programs in clinical development, including Doxitinib mesylate in Phase 1/2 for lung cancer, CL-197 in Phase 1 for HIV, and GEN-725 in Phase 1 for advanced solid tumors.
- Therapeutic areas
- GastroenterologyCardiovascularHematologyOncologyInfectious Diseases
- Modalities
- Small molecule drugsMonoclonal antibodiesADC (Antibody-Drug Conjugate)
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Fosun PharmaFosun Foundation
Beyond the preview
Go deeper on Genuine Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genuine Biotech.